Patients may want to access our experimental medicines outside of clinical trials. Such access is called “Expanded Access” (sometimes called “compassionate use”). We recognize the value of Expanded Access; however, at this time EyeBio is not accepting any requests for Expanded Access. Our lead drug, EYE103, is in the early stages of clinical studies and we are still gathering evidence from these studies. As our studies progress, we may re-evaluate this Expanded Access policy. If our policy changes, we will endeavor to update this page accordingly.
For questions please contact us here. We anticipate we will need 10 working days to acknowledge receipt of such requests.
